Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyra Therapeutics

0.0865
-0.0055-5.98%
Post-market: 0.08900.0025+2.89%19:37 EDT
Volume:1.23M
Turnover:109.48K
Market Cap:5.70M
PE:-0.06
High:0.0952
Open:0.0950
Low:0.0850
Close:0.0920
Loading ...

Lyra Therapeutics Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), aTyr Pharma (ATYR) and Lyra Therapeutics (LYRA)

TIPRANKS
·
14 Mar

Lyra Therapeutics FY 2024 GAAP EPS $(1.43) Misses $(1.38) Estimate, Sales $1.534M Beat $1.524M Estimate

Benzinga
·
14 Mar

Press Release: Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
14 Mar

Lyra Therapeutics Pursues ENLIGHTEN 2 Trial for LYR-210

TIPRANKS
·
11 Jan

Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know

Zacks
·
10 Jan

Lyra Therapeutics Restructures Board of Directors

TIPRANKS
·
14 Dec 2024

Lyra Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
14 Nov 2024

Lyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial Outcomes

TIPRANKS
·
14 Nov 2024

Lyra Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
13 Nov 2024

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
13 Nov 2024

Lyra Therapeutics Q3 2024 GAAP EPS $(0.18) Beats $(0.23) Estimate, Sales $195.000K Miss $320.000K Estimate

Benzinga
·
13 Nov 2024

Lyra Therapeutics reports Q3 EPS (18c), consensus (23c)

TIPRANKS
·
13 Nov 2024

Lyra Therapeutics Q3 EPS USD -0.18

THOMSON REUTERS
·
13 Nov 2024

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
13 Nov 2024

Lyra Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
01 Nov 2024